Burning Rock Biotech Ltd. posts Q3 revenue of RMB 131.6 million

Reuters

11/20

<a href="https://laohu8.com/S/BNR">Burning Rock Biotech</a> Ltd. posts Q3 revenue of RMB 131.6 million

Burning Rock Biotech Ltd. reported third quarter 2025 revenues of RMB 131.6 million, an increase of 2% year-over-year and a decrease of 11% sequentially. Central lab revenues were RMB 36.8 million, down 8% year-over-year and 10% quarter-over-quarter. Gross profit for the quarter was RMB 98.8 million, up 8% year-over-year. Net loss narrowed to RMB 16.8 million from RMB 35.7 million a year earlier, representing a 53% reduction. Adjusted EBITDA (Non-GAAP) was negative RMB 5.4 million, improving 67% year-over-year. The company achieved positive operating cash flow of RMB 16.4 million in the third quarter. Overseas revenues increased by 33% and pharma revenues rose by 72% for the first nine months of 2025 compared with the same period in 2024. Business developments included the use of the OncoCompass Focus ctDNA assay in the FAVOUR study and the submission and publication of the PROMISE study for a 9-cancer early detection test.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Burning Rock Biotech Ltd. published the original content used to generate this news brief on November 20, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2584900652"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584900652\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584900652?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 14:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584900652","market":"us","top_or_hot":-1,"title":"Burning Rock Biotech Ltd. posts Q3 revenue of RMB 131.6 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BNR\">Burning Rock Biotech</a> Ltd. posts Q3 revenue of RMB 131.6 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Burning Rock Biotech Ltd. reported third quarter 2025 revenues of RMB 131.6 million, an increase of 2% year-over-year and a decrease of 11% sequentially. Central lab revenues were RMB 36.8 million, down 8% year-over-year and 10% quarter-over-quarter. Gross profit for the quarter was RMB 98.8 million, up 8% year-over-year. Net loss narrowed to RMB 16.8 million from RMB 35.7 million a year earlier, representing a 53% reduction. Adjusted EBITDA (Non-GAAP) was negative RMB 5.4 million, improving 67% year-over-year. The company achieved positive operating cash flow of RMB 16.4 million in the third quarter. Overseas revenues increased by 33% and pharma revenues rose by 72% for the first nine months of 2025 compared with the same period in 2024. Business developments included the use of the OncoCompass Focus ctDNA assay in the FAVOUR study and the submission and publication of the PROMISE study for a 9-cancer early detection test.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Burning Rock Biotech Ltd. published the original content used to generate this news brief on November 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Burning Rock Biotech Ltd. posts Q3 revenue of RMB 131.6 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBurning Rock Biotech Ltd. posts Q3 revenue of RMB 131.6 million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-20 14:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BNR\">Burning Rock Biotech</a> Ltd. posts Q3 revenue of RMB 131.6 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Burning Rock Biotech Ltd. reported third quarter 2025 revenues of RMB 131.6 million, an increase of 2% year-over-year and a decrease of 11% sequentially. Central lab revenues were RMB 36.8 million, down 8% year-over-year and 10% quarter-over-quarter. Gross profit for the quarter was RMB 98.8 million, up 8% year-over-year. Net loss narrowed to RMB 16.8 million from RMB 35.7 million a year earlier, representing a 53% reduction. Adjusted EBITDA (Non-GAAP) was negative RMB 5.4 million, improving 67% year-over-year. The company achieved positive operating cash flow of RMB 16.4 million in the third quarter. Overseas revenues increased by 33% and pharma revenues rose by 72% for the first nine months of 2025 compared with the same period in 2024. Business developments included the use of the OncoCompass Focus ctDNA assay in the FAVOUR study and the submission and publication of the PROMISE study for a 9-cancer early detection test.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Burning Rock Biotech Ltd. published the original content used to generate this news brief on November 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL23gkwK:1","article_id":"2584900652","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584900652","pubTimestamp":1763620318,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Burning Rock Biotech Ltd. reported third quarter 2025 revenues of RMB 131.6 million, an increase of 2% year-over-year and a decrease of 11% sequentially. Central lab revenues were RMB 36.8 million, down 8% year-over-year and 10% quarter-over-quarter. Gross profit for the quarter was RMB 98.8 million, up 8% year-over-year. Net loss narrowed to RMB 16.8 million from RMB 35.7 million a year earlier, representing a 53% reduction. Adjusted EBITDA  was negative RMB 5.4 million, improving 67% year-over-year. The company achieved positive operating cash flow of RMB 16.4 million in the third quarter. Overseas revenues increased by 33% and pharma revenues rose by 72% for the first nine months of 2025 compared with the same period in 2024. Business developments included the use of the OncoCompass Focus ctDNA assay in the FAVOUR study and the submission and publication of the PROMISE study for a 9-cancer early detection test.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BNR":"燃石医学"},"translate_title":"燃石生物科技有限公司第三季度营收为1.316亿元人民币","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNR":0.9},"content_text":"Burning Rock Biotech Ltd. posts Q3 revenue of RMB 131.6 million\n    \n\n        Burning Rock Biotech Ltd. reported third quarter 2025 revenues of RMB 131.6 million, an increase of 2% year-over-year and a decrease of 11% sequentially. Central lab revenues were RMB 36.8 million, down 8% year-over-year and 10% quarter-over-quarter. Gross profit for the quarter was RMB 98.8 million, up 8% year-over-year. Net loss narrowed to RMB 16.8 million from RMB 35.7 million a year earlier, representing a 53% reduction. Adjusted EBITDA (Non-GAAP) was negative RMB 5.4 million, improving 67% year-over-year. The company achieved positive operating cash flow of RMB 16.4 million in the third quarter. Overseas revenues increased by 33% and pharma revenues rose by 72% for the first nine months of 2025 compared with the same period in 2024. Business developments included the use of the OncoCompass Focus ctDNA assay in the FAVOUR study and the submission and publication of the PROMISE study for a 9-cancer early detection test.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Burning Rock Biotech Ltd. published the original content used to generate this news brief on November 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}